Skip to content

Omnicell OMCL Additional Paid-In Capital

Additional Paid-In Capital at other companies

Baxter International logo
Baxter InternationalBAX
$6.21B-1.5%
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
$1.96B+4.5%
Guardian Pharmacy Services logo
Guardian Pharmacy ServicesGRDN
$141.19M+9.1%
ICU Medical logo
ICU MedicalICUI
$1.47B+3.5%
Haemonetics logo
HaemoneticsHAE
$554.14M+5.9%
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
$1.26B+2.1%

Other financials

Income statement

See full
Revenue$309.9M+14.9%
Gross profit$140.4M+26.5%
Operating income$16.9M+245%
Net income$11.4M+262%
EPS (diluted)$0.25+267%

Balance sheet

See full
Cash & equivalents$291.0M-29.8%
Total debt$34.3M-23.1%
Total equity$1.3B0.0%
Total assets$2.0B-6.8%

Cash flow

See full
Operating cash flow$54.5M+110%
CapEx$12.4M+11.3%
Free cash flow$42.1M+185%

Valuation

See full
Market cap$1.75B-7.2%
Enterprise value$1.49B-0.4%
P/E113.2×
P/S1.4×-0.2×

Profitability

See full
Gross margin43.5%+0.4pp
Operating margin2.7%+1.8pp
Net margin1.7%+1.1pp
FCF margin9.3%-1.7pp

Returns & leverage

See full
Return on equity1.6%+1.1pp
Debt / equity0.0×
Current ratio1.5×+0.1×

Where this comes from

Reported directly by Omnicell in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Omnicell’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omnicell's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omnicell's additional paid-in capital?
Omnicell (OMCL) reported additional paid-in capital of $1.24B in Q1 2026.
How has Omnicell's additional paid-in capital changed year-over-year?
Omnicell's additional paid-in capital increased by 4.5% year-over-year, from $1.19B to $1.24B.
What is the long-term trend for Omnicell's additional paid-in capital?
Over 5 years (2020 to 2025), Omnicell's additional paid-in capital has grown at a 5.9% compound annual growth rate (CAGR), from $920.36M to $1.22B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.